目的 探討?zhàn)B胃舒膠囊聯(lián)合吉法酯片治療慢性萎縮性胃炎的臨床療效。方法 將2022年11月—2024年12月石家莊市人民醫(yī)院收治的慢性萎縮性胃炎患者共計(jì)82例納入研究。按隨機(jī)數(shù)字表法將所有患者分為對(duì)照組（41例）、治療組（41例）。對(duì)照組口服吉法酯片，3次/d，2片/次。治療組在對(duì)照組基礎(chǔ)上口服養(yǎng)胃舒膠囊，2次/d，2粒/次。兩組患者持續(xù)治療3個(gè)月。對(duì)比患者的臨床療效、胃鏡病理評(píng)分、胃腸道激素和血清細(xì)胞因子。結(jié)果 對(duì)照組患者的總有效率為80.49%，明顯低于治療組的總有效率95.12%，組間比較差異顯著（P＜0.05）。兩組治療后的胃鏡病理評(píng)分低于治療前（P＜0.05），治療組治療后的胃鏡病理評(píng)分低于對(duì)照組（P＜0.05）。治療后，兩組的胃蛋白酶原比值（PGR）、胃泌素-17（G-17）、生長抑素（SS）均比治療前高（P＜0.05），且治療組的PGR、G-17、SS高于對(duì)照組（P＜0.05）。兩組治療后的轉(zhuǎn)化生長因子-β1（TGF-β1）、人表皮生長因子（hEGF）、趨化因子C-X3-C-基元配體1（CX3CL1）顯著降低，治療組治療后的TGF-β1、hEGF、CX3CL1低于對(duì)照組（P＜0.05）。結(jié)論 養(yǎng)胃舒膠囊聯(lián)合吉法酯片可提高慢性萎縮性胃炎的臨床療效，減輕胃黏膜病理改變，調(diào)節(jié)胃腸激素的分泌，延緩纖維化進(jìn)程。

Objective To explore the clinical efficacy of Yangweishu Capsules combined with Gefitil Tablets in treatment of chronic atrophic gastritis.Methods 82 Patients with chronic atrophic gastritis admitted to Shijiazhuang People's Hospital from November 2022 to December 2024 were included, and were divided into control group (n = 41) and treatment group (n = 41) according to the random number table method. The control group patients took orally Gefitil Tablets, 3 times daily, 2 tablets per time. On the basis of the control group, the treatment group patients took orally Yangweishu Capsules, twice daily, 2 capsules/time. Two groups of patients received continuous treatment for 3 months. The clinical efficacy, gastroscopy pathological score, gastrointestinal hormones, and serum cytokines were compared between two groups.Results The total effective rate of the control group was 80.49%, which was significantly lower than the 95.12% of the treatment group, and the difference between the groups was significant (P < 0.05). The gastroscopy pathological scores in two groups after treatment were lower than those before treatment (P < 0.05), and the gastroscopy pathological scores in the treatment group were lower than those in the control group after treatment (P < 0.05). After treatment, the pepsinogen ratio (PGR), gastrin-17 (G-17), and somatostatin (SS) in two groups were higher than those before treatment (P < 0.05), and the PGR, G-17, and SS in the treatment group were higher than those in the control group (P < 0.05). After treatment, the serum levels of transforming growth factor-β1 (TGF-β1), human epidermal growth factor (hEGF), and chemokine C-X3-C-based ligand 1 (CX3CL1) were significantly reduced in two groups, and the serum levels of TGF-β1, hEGF, and CX3CL1 in the treatment group were lower than those in the control group (P < 0.05).Conclusion The combination of Yangweishu Capsules and Gefitil Tablets can improve the clinical efficacy of chronic atrophic gastritis, alleviate pathological changes in the gastric mucosa, regulate the secretion of gastrointestinal hormones, and delay the fibrosis process.

R975

河北省衛(wèi)生健康委醫(yī)學(xué)科學(xué)研究課題計(jì)劃項(xiàng)目（20210198）